Brand

The largest practical benefit of a brand is that it lowers what a customer must know to say yes. A buyer facing a medicine, a car or a fleece jacket cannot test every claim. Where the cost of being wrong is high and the product is hard to inspect, the trusted name does the inspecting. The logic points to health, safety, finance and any purchase that is expensive to reverse as the places where brands should matter most.

The second benefit is that a brand changes what a company is allowed to do. If it cannot decide a hard case, it is only a tagline.

The third is resilience. Tylenol’s recovery to a 35% share within about fifteen months is consistent with restored trust, but it cannot isolate the effects of the recall, new packaging, product availability or other market changes. The recall cost $100 million, on top of the sales lost while the product was off the shelf; that is evidence of a costly response, not a direct measure of customer perception.

Finally, a brand can carry meaning beyond the product. On September 14, 2022, Yvon Chouinard announced that the Chouinard family had transferred all of Patagonia’s ownership to a purpose trust and a nonprofit, so that profits not reinvested would go to fighting the climate crisis. That is the extreme case of a company treating its promise as an operating constraint rather than a marketing position. Whether customers reward it is a separate, unproven question. The point for strategy is that the company chose a structure in which it cannot easily break the promise.

The sharpest failure is a promise the company knew was false. On September 18, 2015, the EPA said more than 480,000 cars contained software that turned on full emissions controls only during testing, letting them emit up to 40 times the allowed pollution. In January 2017 Volkswagen agreed to plead guilty to three felony counts over about 590,000 vehicles and to pay $4.3 billion: $2.8 billion in criminal penalties and $1.5 billion in civil resolutions. The buyers had paid for a prediction that turned out to be a fabrication. Tylenol’s case is the mirror image: J&J was the victim of a crime and took the loss anyway, and the name survived. Volkswagen was the perpetrator.

A brand also breaks when management measures the wrong thing. Coca-Cola’s 1985 reformulation was preferred in taste tests of nearly 200,000 consumers, and it still failed in the market, because a sip test with the name removed measures the drink but not the brand. The Neuron study points the same way: the label can change the experience. A blind test answers a question about the product without its brand cue; to estimate what the brand adds, compare otherwise similar branded and blind conditions. Coca-Cola’s own account says the tests missed the bond many consumers felt with the original formula, a limit for any survey that measures product attributes without asking what the name means.

Finally, a brand is easy to overclaim. Recognition is not trust, and trust is not a price premium. Patagonia’s ownership structure shows conviction, but it does not show how much of the company’s sales come from its stance rather than its jackets, and the same caution applies to most brand valuations. A brand promise also has a cost. J&J’s $100 million recall was a real cash outlay made on the belief that the name was worth more. Companies that cannot or will not pay when the promise is tested hold a logo, not a brand.